These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 33309558)

  • 21. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.
    Genton B; Betuela I; Felger I; Al-Yaman F; Anders RF; Saul A; Rare L; Baisor M; Lorry K; Brown GV; Pye D; Irving DO; Smith TA; Beck HP; Alpers MP
    J Infect Dis; 2002 Mar; 185(6):820-7. PubMed ID: 11920300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allelic family-specific humoral responses to merozoite surface protein 2 (MSP2) in Gabonese residents with Plasmodium falciparum infections.
    Ekala MT; Jouin H; Lekoulou F; Mercereau-Puijalon O; Ntoumi F
    Clin Exp Immunol; 2002 Aug; 129(2):326-31. PubMed ID: 12165090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria.
    Metzger WG; Okenu DM; Cavanagh DR; Robinson JV; Bojang KA; Weiss HA; McBride JS; Greenwood BM; Conway DJ
    Parasite Immunol; 2003 Jun; 25(6):307-12. PubMed ID: 14507328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso.
    Somé AF; Bazié T; Zongo I; Yerbanga RS; Nikiéma F; Neya C; Taho LK; Ouédraogo JB
    Parasit Vectors; 2018 May; 11(1):323. PubMed ID: 29843783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice.
    Balam S; Jafarshad A; Servis C; Frank G; Reed S; Pink R; Druilhe P; Spertini F; Corradin G
    Vaccine; 2016 Mar; 34(13):1566-1574. PubMed ID: 26874325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
    Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
    Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
    Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acetalated Dextran Microparticulate Vaccine Formulated via Coaxial Electrospray Preserves Toxin Neutralization and Enhances Murine Survival Following Inhalational Bacillus Anthracis Exposure.
    Gallovic MD; Schully KL; Bell MG; Elberson MA; Palmer JR; Darko CA; Bachelder EM; Wyslouzil BE; Keane-Myers AM; Ainslie KM
    Adv Healthc Mater; 2016 Oct; 5(20):2617-2627. PubMed ID: 27594343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
    Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
    Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.
    Mehrizi AA; Rezvani N; Zakeri S; Gholami A; Babaeekhou L
    Med Microbiol Immunol; 2018 Apr; 207(2):151-166. PubMed ID: 29397427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibodies against a Plasmodium falciparum RON12 inhibit merozoite invasion into erythrocytes.
    Ito D; Takashima E; Yamasaki T; Hatano S; Hasegawa T; Miura K; Morita M; Thongkukiatkul A; Diakite M; Long CA; Sattabongkot J; Udomsangpetch R; Iriko H; Ishino T; Tsuboi T
    Parasitol Int; 2019 Feb; 68(1):87-91. PubMed ID: 30342119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction in the mean number of Plasmodium falciparum genotypes in Gambian children immunized with the malaria vaccine SPf66.
    Haywood M; Conway DJ; Weiss H; Metzger W; D'Alessandro U; Snounou G; Targett G; Greenwood B
    Trans R Soc Trop Med Hyg; 1999 Feb; 93 Suppl 1():65-8. PubMed ID: 10450429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.
    Genton B; Al-Yaman F; Anders R; Saul A; Brown G; Pye D; Irving DO; Briggs WR; Mai A; Ginny M; Adiguma T; Rare L; Giddy A; Reber-Liske R; Stuerchler D; Alpers MP
    Vaccine; 2000 May; 18(23):2504-11. PubMed ID: 10775784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria.
    al-Yaman F; Genton B; Anders R; Taraika J; Ginny M; Mellor S; Alpers MP
    Parasite Immunol; 1995 Sep; 17(9):493-501. PubMed ID: 8552419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas.
    Jepsen MP; Jogdand PS; Singh SK; Esen M; Christiansen M; Issifou S; Hounkpatin AB; Ateba-Ngoa U; Kremsner PG; Dziegiel MH; Olesen-Larsen S; Jepsen S; Mordmüller B; Theisen M
    J Infect Dis; 2013 Aug; 208(3):479-88. PubMed ID: 23624363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.
    Jäschke A; Coulibaly B; Remarque EJ; Bujard H; Epp C
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Passive immunoprotection of Plasmodium falciparum-infected mice designates the CyRPA as candidate malaria vaccine antigen.
    Dreyer AM; Matile H; Papastogiannidis P; Kamber J; Favuzza P; Voss TS; Wittlin S; Pluschke G
    J Immunol; 2012 Jun; 188(12):6225-37. PubMed ID: 22593616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGCG disaggregates amyloid-like fibrils formed by Plasmodium falciparum merozoite surface protein 2.
    Chandrashekaran IR; Adda CG; Macraild CA; Anders RF; Norton RS
    Arch Biochem Biophys; 2011 Sep; 513(2):153-7. PubMed ID: 21784057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid interactions modulate the structural and antigenic properties of the C-terminal domain of the malaria antigen merozoite surface protein 2.
    Das SC; Morales RAV; Seow J; Krishnarjuna B; Dissanayake R; Anders RF; MacRaild CA; Norton RS
    FEBS J; 2017 Aug; 284(16):2649-2662. PubMed ID: 28618199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1.
    Burns JM; Flaherty PR; Romero MM; Weidanz WP
    Vaccine; 2003 May; 21(17-18):1843-52. PubMed ID: 12706668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.